The pharmacological inhibition of HB-EGF-EGFR signaling with erlotinib results in anti-angiogenic effects, inhibits cancer cell growth both in vitro and in vivo, and prevents multiple myeloma progression [44]. This evidence concerns the gene EGF and plasma cell myeloma.